Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

An unlicensed vaccine made by Merck was approved for use a week after the DRC declared the Ebola outbreak in August.

Merck's Ebola vaccine helps combat deadly outbreak in the Congo as the virus spreads

American Express

Cisco Systems

Genuine Parts

Coca-Cola

In this volatile market, blue-chip stocks will get you through. Here are five of the bluest stocks to buy today.

Five Great Blue-Chip Stocks to Buy.

Amgen

Eli Lilly

A federal judge on Monday blocked the Trump administration from implementing a new rule that would force pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

US judge halts Trump administration rule requiring drug prices in TV ads

Bausch Health Companies Inc

Endo International

Mallinckrodt PLC

Pharmaceutical and biotech stocks skidded Monday on expectations that President Donald Trump will sign an executive order to corral drug prices. This would be his 23rd executive order in 2019.

Medical Stocks Hammered As Trump Mulls Order To Corral Drug Prices

Johnson & Johnson

Rogers

Bristol-Myers

Gilead Sciences

Novo Nordisk

Novartis

Pfizer

Sanofi

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

AbbVie

Bayer AG

GlaxoSmithKline

Roche Holding AG

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Allergan

Celgene

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

Acer Therapeutics

Biohaven Pharmaceutical Hld

Intra-Cellular Therapies

Karyopharm Therapeutics

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Keytruda continues to dominate its field, applications in more critical situations could be possible.

Merck: Don't Miss It

Merck’s (NYSE:MRK) anti-infectious drugs business is the company’s largest therapeutic area and it will likely decline in low-single-digits from about $10.9 billion in 2018 to $10.4 billion in 2021, according to Trefis estimates. This decline will likely be driven by lower sales from Zepatier, In.

Will Merck's #1 Therapeutic Area With $10 Billion In Revenue Grow?

Baxter

Edwards Lifesciences

Health care stocks floundered Wednesday ahead of the Democratic presidential debate and after President Donald Trump signed an order requiring hospitals to disclose their prices upfront.

Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate

Merck Announced FDA approval for Keytruda as a third-line therapy for patients with SCLC.

Merck Throws Its Hat Into The Ring With Keytruda For Treating Subset Of Lung Cancer Patients

Merck (MRK) closed the most recent trading day at $85.23, moving -0.33% from the previous trading session.

Merck (MRK) Stock Moves -0.33%: What You Should Know

President Trump issues an executive order that would pressure insurers, doctors and other providers to disclose more information about health-care prices.

Trump to issue executive order to increase transparency in health-care prices

Merck & Co Chief Executive Ken Frazier said on Thursday  a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice

Merck & Co., Inc. (NYSE: MRK) is preparing for the departure of its CEO Kenneth Frazier and searching internally for a replacement, according to Bloomberg.

Report: Merck Searching Internally For Next CEO

Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

Merck's Keytruda Gets 2nd Label Expansion Approval in June

AstraZeneca

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

American Airlines

Amazon

Broadcom

Beyond Meat

Chewy

General Electric

 Luckin Coffee

United Technologies

A lot happened in the world of business during the week of June 14, 2019.

Our Top 10 Stock Moves & News Items for the Week

Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.

5 Biggest Blockbuster Drugs of the Future

These big pharma stocks all have a Zacks Rank #2 or better.

3 Big Pharma Stocks to Buy Right Now

Merck & Co. Inc. (NYSE: MRK) may still be up in 2019, and it may be better off for now than rival Pfizer, but the reality is that Merck shares have underperformed the market as the pharmaceutical and health care companies are facing risks that may come sooner rather than later.

High Hopes and Expectations for Merck’s First Investor Day in Years

Biogen

Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

Here are five reasons why investors may consider betting on Merck (MRK) stock

News for Merck Stock (MRK)